MediciNova (MNOV) Drops Amid Positive Findings

MediciNova, Inc. MNOV subsided 4% to $7.39. MediciNova announced after Wednesday's close that the medical journal Drug and Alcohol Dependence published an article detailing positive findings from the company's completed Phase 1b clinical trial of MN-166 in methamphetamine dependence. Share volume was 519,000, compared to an all-day average of 151,000